Emami Misses FY26 Revenue Guidance; Eyes FY27 Recovery

4 min read     Updated on 24 May 2026, 11:13 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Emami Limited reported a 1% decline in FY26 revenue to ₹3,780 crore, missing its guidance of 10% growth. Q4 net profit fell to ₹143 crore from ₹162 crore YoY, with EBITDA margins contracting to 20.2%. Despite the talc business facing margin headwinds, management expects a recovery in FY27 driven by double-digit growth in summer brands and international business. The Board also approved the re-appointment of the Vice-Chairman & Managing Director and declared an interim dividend of ₹10 per share.

powered bylight_fuzz_icon
40897716

*this image is generated using AI for illustrative purposes only.

Emami reported its audited financial results for the quarter and year ended March 31, 2026, revealing a decline in annual revenue and profitability. The company's FY26 revenue recorded a degrowth of 1%, starkly missing its own guidance of 10% revenue growth. This performance underscores the challenges faced during the fiscal year, compounded by a broad-based year-on-year decline in Q4 metrics. Despite the disappointing FY26 outturn, management has expressed confidence in its FY27 strategy, targeting double-digit growth for key summer brands and a recovery in its international business. The Board of Directors also approved the re-appointment of Shri Harsha Vardhan Agarwal as Vice-Chairman & Managing Director for a further period of five years.

Q4 Financial Performance at a Glance

The following table summarises Emami's key Q4 financial metrics compared to the year-ago period:

Metric: Q4 Current Q4 YoY Change
Revenue: ₹925 crore ₹963 crore Decline
EBITDA: ₹187 crore ₹219 crore Decline
EBITDA Margin: 20.2% 22.8% Contraction
Consolidated Net Profit: ₹143 crore ₹162 crore Decline

Revenue and Profitability Under Pressure

Emami's Q4 revenue stood at ₹925 crore, declining from ₹963 crore reported in the corresponding quarter of the previous year. This top-line contraction reflects the broader pressure on the company's business during the quarter, attributed to unfavourable seasonal conditions affecting the summer portfolio and geopolitical disruptions in West Asia. The company also fell short of achieving double-digit revenue growth for the full year, marking a notable miss on a key performance benchmark.

EBITDA and Margin Contraction

On the operational front, EBITDA for Q4 came in at ₹187 crore, down from ₹219 crore in the year-ago period. The EBITDA margin narrowed to 20.2% from 22.8% YoY, indicating that cost pressures or lower operating leverage weighed on profitability during the quarter. Despite this, the company improved its gross margins to 68.4%, an expansion of 250 basis points, reflecting disciplined cost management and operational efficiencies. Management also highlighted lower margins in the talc category, while noting increased summer demand as a potential growth driver.

Net Profit Declines Year-on-Year

Emami's consolidated net profit for Q4 declined to ₹143 crore from ₹162 crore in the same quarter last year. The fall in net profit is consistent with the weaker revenue and EBITDA performance observed during the period, reflecting a challenging operating environment for the company.

FY26 Revenue Misses Guidance by Wide Margin

Beyond the quarterly results, Emami's full-year performance has also come under scrutiny. The company's FY26 revenue recorded a degrowth of 1%, a sharp divergence from its own guidance of 10% revenue growth. For the full year, revenues stood at ₹3,780 crore, while EBITDA stood at ₹964 crore and PAT at ₹775 crore. The following table highlights the extent of the guidance miss:

Parameter: Details
FY26 Revenue Growth (Actual): -1% (Degrowth)
FY26 Revenue Growth (Guidance): 10%
Variance: 11 percentage points

This significant gap between actual performance and stated guidance raises questions about the headwinds the company encountered during the fiscal year, compounding the pressure already visible in the quarterly numbers.

Talc Business Segment Performance

Management provided additional colour on the talc business, which contributed approximately ₹300 crore in FY26, accounting for around 10% of the company's overall revenue. The segment was flagged as a margin headwind during the year, with management specifically noting lower margins in the talc category as a factor weighing on overall profitability.

Parameter: Details
Talc Business Revenue (FY26): ~₹300 crore
Share of Overall Revenue: ~10%

FY27 Outlook: Management Targets Recovery

Looking ahead, Emami's management has outlined a clear strategy for FY27, expressing confidence in a meaningful recovery. The company expects double-digit growth for its summer brands Navratna and Dermicool in H1 FY27, driven by increased seasonal demand. On the international front, the business forecasts strong double-digit growth from Q2 FY27, following anticipated single-digit growth in Q1 FY27. The following table summarises the key management guidance for FY27:

Parameter: FY27 Guidance
Summer Brands (Navratna & Dermicool) Growth — H1 FY27: Double-digit
International Business Growth — Q1 FY27: Single-digit
International Business Growth — From Q2 FY27: Strong double-digit

Strategic Investments and Dividend

During the year, the company made strategic investments to strengthen its future growth portfolio. It increased its stake in Axiom Ayurveda, making it a subsidiary, and is acquiring a majority stake in IncNut to bolster its presence in the personalised beauty segment. The Board declared interim dividends aggregating to ₹10 per share, amounting to a total payout of ₹436.5 crore.

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
-3.07%-5.09%-11.23%-21.51%-33.70%-20.04%

Can Emami realistically achieve double-digit growth for Navratna and Dermicool in H1 FY27 given the recurring risk of unfavourable seasonal conditions that hurt FY26 performance?

How will Emami's acquisition of a majority stake in IncNut and increased stake in Axiom Ayurveda contribute to revenue diversification and margin improvement over the next two to three years?

With geopolitical disruptions in West Asia cited as a key headwind, what alternative markets or strategies is Emami pursuing to de-risk its international business concentration?

Emami Limited Schedules Investor Conference Call on 21 May 2026 Post Q4 FY26 Results

1 min read     Updated on 14 May 2026, 06:34 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Emami Limited has scheduled a conference call with analysts and investors on 21 May 2026 at 4:00 PM IST, following the announcement of its Q4 FY26 financial results. The call will be attended by senior management including the Wholetime Director & Vice Chairman, Mr. Mohan Goenka, along with heads of international business, growth, healthcare, sales, and finance. The intimation was filed on 14 May 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dial-in access has been provided for participants in India, the USA, UK, Singapore, and Hong Kong.

powered bylight_fuzz_icon
40309465

*this image is generated using AI for illustrative purposes only.

Emami Limited has announced a conference call with analysts and investors scheduled for Thursday, 21 May 2026 at 4:00 PM IST, to be held following the declaration of the company's Q4 FY26 financial results. The intimation was filed by the Company Secretary & Compliance Officer, Ravi Varma, on 14 May 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Details of the call are also available on the company's official website.

Management Participants

The conference call will feature participation from a broad cross-section of Emami's senior leadership team, covering key functional areas including international business, growth, healthcare, sales, and finance. The following management representatives are scheduled to participate:

Role: Name
Wholetime Director & Vice Chairman Mr. Mohan Goenka
CEO (International Business) Mr. Vivek Dhir
Chief Growth Officer Mr. Dhruv Aggarwal
President (Healthcare) Mr. Gul Raj Bhatia
President (Sales) Mr. Manish Gupta
President (Finance & IR) Mr. Rajesh Sharma

Conference Call Details

The call is open to participants across multiple geographies, with dial-in numbers provided for India and select international locations. The following table summarises the key logistical details:

Parameter: Details
Date & Time (IST) Thursday, 21 May 2026, 4:00 PM
Hong Kong / Singapore 6:30 PM
UK 11:30 AM
New York 6:30 AM
India – Universal Access +91 22 6280 1259 / +91 22 7115 8160
USA (Toll-free) 18667462133
UK (Toll-free) 08081011573
Singapore (Toll-free) 8001012045
Hong Kong (Toll-free) 800964448

Further Information

For additional details regarding the conference call, participants may contact the following representatives:

The full schedule of investor calls is also accessible through Emami's investor relations section at the company's official website.

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
-3.07%-5.09%-11.23%-21.51%-33.70%-20.04%

How might Emami's Q4 FY26 results reflect the impact of rural consumption recovery and premiumization trends on its core product categories?

What strategic updates could Emami's international business leadership signal regarding expansion plans in emerging markets like MENA, SAARC, or Africa?

How is Emami positioned to navigate rising input costs for key raw materials like menthol and herbal ingredients in FY27?

More News on Emami

1 Year Returns:-33.70%